Equity trader on Orphazyme surprise: "It's a bit like Gamestop all over again"

Orphazyme's share price has taken a wild ride over the past day – both in the US and Denmark. According to Mads Zink, head of Danish Cash Equities at Danske Bank, a Gamestop effect is happening.

Photo: Jens Dresling

Orphazyme trended on social media in the US on Thursday as its share price rocketed for no clear reason.

The biotech company has also attracted attention in Denmark, where the share price rose by 40 percent up to DKK 47.6 on Friday – a significant increase, but far less than the rise in the US.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs